Case number 2022-1258
Janssen Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 7, 2024 | 0 | JANSSEN PHARMACEUTICALS, INC. v. TEVA PHARMACEUTICALS USA, INC. [OPINION] [precedential] (0) |
| Aug 7, 2023 | 63 | Notice from Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. of withdrawal of the appearance of Andrew Robert Quirk. Service: 08/07/2023 by email. [941159] [22-1258] [Andrew Cohen] [Entered: 08/07/2023 03:32 PM] (1) |
| Jul 31, 2023 | 62 | Response to notice of oral argument from Appellants Mylan Laboratories Ltd. and Teva Pharmaceuticals USA, Inc.. Service: 07/31/2023 by email. [939567] [22-1258] [John O'Quinn] [Entered: 07/31/2023 02:55 PM] (1) |
| Jul 28, 2023 | 61 | Response to notice of oral argument from Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. Service: 07/28/2023 by email. [939196] [22-1258] [Barbara Mullin] [Entered: 07/28/2023 01:28 PM] (1) |
| Jul 21, 2023 | 60 | NOTICE OF ORAL ARGUMENT. Panel: 2309F. Case scheduled September 8, 2023. Response to Notice of Oral Argument due: 08/04/2023. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [937746] [MJL] [Entered: 07/21/2023 04:16 PM] (2) |
| Jun 2, 2023 | 59 | Letter from Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. Attorney Availability. Service: 06/02/2023 by email. [927442] [22-1258] [Barbara Mullin] [Entered: 06/02/2023 02:10 PM] (2) |
| Jan 13, 2023 | 58 | Notice from Appellant Teva Pharmaceuticals USA, Inc. regarding conflicts with oral argument. Service: 01/13/2023 by email. [897073] [22-1258] [John O'Quinn] [Entered: 01/13/2023 06:09 PM] (1) |
| Jan 13, 2023 | 57 | 6 paper copies of Doc. No. [51], [44], [35] received from Appellants Mylan Laboratories Ltd. and Teva Pharmaceuticals USA, Inc.. [896998] [VDW] [Entered: 01/13/2023 04:09 PM] (0) |
| Jan 13, 2023 | 56 | The following conflict dates submitted by Barbara Mullin for Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV have been accepted by the court: 03/06/2023, 03/07/2023, 03/08/2023, 04/03/2023, 04/04/2023, 04/05/2023, 04/06/2023, 04/07/2023. The following conflicts dates are not accepted at this time: 03/09/2023, 03/10/2023. [896940] [MJL] [Entered: 01/13/2023 02:41 PM] (0) |
| Jan 12, 2023 | 55 | Notice from Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 01/12/2023 by email. [896727] [22-1258] [Barbara Mullin] [Entered: 01/12/2023 05:25 PM] (3) |
| Jan 10, 2023 | 54 | 6 paper copies of Doc. No. [38] received from Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. [896702] [VDW] [Entered: 01/12/2023 04:37 PM] (0) |
| Jan 6, 2023 | 53 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [895224] [KMH] [Entered: 01/06/2023 02:12 PM] (0) |
| Jan 6, 2023 | 52 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [895219] [KMH] [Entered: 01/06/2023 02:08 PM] (1) |
| Dec 23, 2022 | 51 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL APPENDIX FILED by Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc.. Service: 12/23/2022 by email. [892654]--[Edited 01/06/2023 by KMH - compliance review complete] [John O'Quinn] [Entered: 12/23/2022 11:25 AM] (0) |
| Dec 23, 2022 | 50 | MODIFIED ENTRY: CORRECTED APPENDIX FILED by Appellants Mylan Laboratories Limited, Teva Pharmaceuticals USA, Inc. and Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. Service: 12/23/2022 by email. [892645] --[Edited 01/06/2023 by KMH - compliance review complete] [John O'Quinn] [Entered: 12/23/2022 11:05 AM] (1265) |
| Dec 22, 2022 | 49 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Mylan Laboratories Limited, Teva Pharmaceuticals USA, Inc. and Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc., Appendix [47], [48], is not in compliance with the rules of this court (see attached). Compliant documents due on 12/30/2022. Service as of this date by the Clerk of Court. [892410] [KMH] [Entered: 12/22/2022 11:24 AM] (2) |
| Dec 6, 2022 | 48 | CONFIDENTIAL APPENDIX FILED by Appellees Janssen Pharmaceutica NV, Janssen Pharmaceuticals, Inc. and Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc.. Service: 12/06/2022 by email. [888736] [22-1258] This document is non-compliant. See Doc No. [49] [John O'Quinn] [Entered: 12/06/2022 02:45 PM] (0) |
| Dec 6, 2022 | 47 | APPENDIX FILED by Appellees Janssen Pharmaceutica NV, Janssen Pharmaceuticals, Inc. and Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc.. Service: 12/06/2022 by email. [888723] [22-1258] This document is non-compliant. See Doc No. [49] [John O'Quinn] [Entered: 12/06/2022 02:31 PM] (1265) |
| Dec 6, 2022 | 46 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellees Janssen Pharmaceutica NV, Janssen Pharmaceuticals, Inc. and Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc.. Service: 12/06/2022 by email. [888712] [22-1258] [William Burgess] [Entered: 12/06/2022 01:54 PM] (2) |
| Dec 6, 2022 | 45 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc.. Service: 12/06/2022 by email. [888707] [22-1258] [William Burgess] [Entered: 12/06/2022 01:50 PM] (2) |
| Nov 29, 2022 | 44 | MODIFIED ENTRY: REPLY BRIEF FILED by Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc.. Service: 11/29/2022 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [887062] --[Edited 12/09/2022 by KMH - compliance review complete] [John O'Quinn] [Entered: 11/29/2022 06:23 PM] (46) |
| Nov 9, 2022 | 43 | ORDER granting motion to extend time to file brief [42] filed by Appellants Teva Pharmaceuticals USA, Inc. and Mylan Laboratories Limited. The reply brief is due 11/29/2022. Service as of this date by the Clerk of Court. [883231] [LMS] [Entered: 11/09/2022 03:22 PM] (2) |
| Nov 4, 2022 | 42 | MOTION of Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc. to extend the time to 11/29/2022 to file brief. Service: 11/04/2022 by email. [882186] [22-1258] [William Burgess] [Entered: 11/04/2022 09:58 AM] (8) |
| Sep 22, 2022 | 41 | ORDER granting motion to extend time to file brief [40] filed by Appellants. The reply brief is due 11/14/2022. Service as of this date by the Clerk of Court. [873306] [LMS] [Entered: 09/22/2022 08:59 AM] (2) |
| Sep 14, 2022 | 40 | MOTION of Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc. to extend the time to 11/14/2022 to file brief. Service: 09/14/2022 by email. [871703] [22-1258] [William Burgess] [Entered: 09/14/2022 01:07 PM] (8) |
| Sep 6, 2022 | 39 | MODIFIED ENTRY: RESPONSE BRIEF FILED by Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. Service: 09/06/2022 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [870133] --[Edited 09/13/2022 by KMH - compliance review complete] [Barbara Mullin] [Entered: 09/06/2022 04:24 PM] (86) |
| Sep 6, 2022 | 38 | MODIFIED ENTRY: CONFIDENTIAL RESPONSE BRIEF FILED by Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. Service: 09/06/2022 by email. [870128]--[Edited 09/13/2022 by KMH - compliance review complete] [Barbara Mullin] [Entered: 09/06/2022 04:21 PM] (0) |
| Aug 29, 2022 | 37 | Certificate of Interest for Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. Service: 08/29/2022 by email. [868603] [22-1258] [Barbara Mullin] [Entered: 08/29/2022 10:42 AM] (3) |
| Aug 29, 2022 | 36 | Entry of appearance for Barbara L. Mullin; Aron R. Fischer; Andrew D. Cohen; Meghan R. Larywon; A. Robert Quirk as counsel for Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. Service: 08/29/2022 by email. [868601] [22-1258] [Barbara Mullin] [Entered: 08/29/2022 10:41 AM] (2) |
| Jul 5, 2022 | 35 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL OPENING BRIEF FILED by Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc.. Service: 07/05/2022 by email. [859011]--[Edited 07/05/2022 by JCW - compliance review complete] [John O'Quinn] [Entered: 07/05/2022 11:58 AM] (0) |
| Jul 5, 2022 | 34 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc.. Service: 07/05/2022 by email. See Fed. Cir. R. 31. [859008] --[Edited 07/05/2022 by JCW - compliance review complete] [John O'Quinn] [Entered: 07/05/2022 11:53 AM] (224) |
| Jun 23, 2022 | 33 | ORDER filed denying [30] the motion to waive the requirements of Federal Circuit Rule 25.1(d)(1) without prejudice to Appellants filing a corrected brief or a new motion within 10 days of the date of filing of this order. Service as of this date by the Clerk of Court. [856970] [LMS] [Entered: 06/23/2022 12:42 PM] (3) |
| Jun 7, 2022 | 32 | ORDER granting motion to extend time to file brief [31] to the extent that the response brief is due no later than September 6, 2022. Service as of this date by the Clerk of Court. [853942] [LMS] [Entered: 06/07/2022 09:04 AM] (2) |
| Jun 1, 2022 | 31 | MOTION of Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. to extend the time to 09/06/2022 to file brief. Service: 06/01/2022 by email. [853046] [22-1258] [Aron Fischer] [Entered: 06/01/2022 01:45 PM] (8) |
| May 13, 2022 | 30 | MOTION of Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc. to waive confidentiality requirements. Service: 05/13/2022 by email. [849827] [22-1258] [John O'Quinn] [Entered: 05/13/2022 09:12 PM] (7) |
| May 13, 2022 | 29 | CONFIDENTIAL OPENING BRIEF FILED by Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc.. Service: 05/13/2022 by email. (PENDING COMPLIANCE REVIEW) [849826] [22-1258] [John O'Quinn] [Entered: 05/13/2022 09:10 PM] (0) |
| May 13, 2022 | 28 | OPENING BRIEF FILED by Appellants Teva Pharmaceuticals USA, Inc. and Mylan Laboratories Limited. Service: 05/13/2022 by email. (PENDING COMPLIANCE REVIEW) [849825] [22-1258] [John O'Quinn] [Entered: 05/13/2022 09:09 PM] (224) |
| May 13, 2022 | 27 | Amended Certificate of Interest for Appellant Teva Pharmaceuticals USA, Inc.. Service: 05/13/2022 by email. [849824] [22-1258] [John O'Quinn] [Entered: 05/13/2022 09:02 PM] (2) |
| May 13, 2022 | 26 | Amended Certificate of Interest for Appellant Mylan Laboratories Limited. Service: 05/13/2022 by email. [849817] [22-1258] [Eric Werlinger] [Entered: 05/13/2022 06:14 PM] (4) |
| May 2, 2022 | 25 | Corrected Entry of appearance for John C. O'Quinn; William H. Burgess; Jeanna Wacker; Christopher Jagoe; Justin Bova as counsel for Appellant Teva Pharmaceuticals USA, Inc.. Service: 05/02/2022 by email. [846947] [22-1258] [John O'Quinn] [Entered: 05/02/2022 04:51 PM] (2) |
| Apr 28, 2022 | 24 | NOTICE OF NON-COMPLIANCE: The submission of Appellant Teva Pharmaceuticals USA, Inc., Entry of Appearance [23], is not in compliance with the rules of this court (see attached). Compliant document due on 05/05/2022. Service as of this date by the Clerk of Court. [845900] [JCW] [Entered: 04/28/2022 08:48 AM] (1) |
| Apr 27, 2022 | 23 | Amended Entry of appearance for John C. O'Quinn; William H. Burgess; Jeanna Wacker; Christopher Jagoe; Justin Bova as counsel for Appellant Teva Pharmaceuticals USA, Inc.. Service: 04/27/2022 by email. [845862] [22-1258] This document is non-compliant. See Doc No.[24] [John O'Quinn] [Entered: 04/27/2022 06:16 PM] (2) |
| Apr 14, 2022 | 22 | ORDER granting motion to extend time to file brief [21] filed by Appellants Teva Pharmaceuticals USA, Inc. and Mylan Laboratories Limited. The opening brief is due no later than May 13, 2022. Service as of this date by the Clerk of Court. [842905] [LMS] [Entered: 04/14/2022 08:32 AM] (2) |
| Apr 11, 2022 | 21 | MOTION of Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc. to extend the time to 05/13/2022 to file brief. Service: 04/11/2022 by email. [842400] [22-1258] [William Burgess] [Entered: 04/11/2022 02:22 PM] (6) |
| Feb 11, 2022 | 20 | Notice from Appellant Teva Pharmaceuticals USA, Inc. of withdrawal of appearance of Mira A. Mulvaney. Service: 02/11/2022 by email. [830673] [22-1258] [William Burgess] [Entered: 02/11/2022 01:32 PM] (1) |
| Feb 10, 2022 | 19 | **TEXT ONLY** ORDER granting motion to extend time to file brief [18] filed by Appellants Teva Pharmaceuticals USA, Inc. and Mylan Laboratories Limited. The opening brief is due 04/29/2022. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [830324] [JCW] [Entered: 02/10/2022 09:37 AM] (0) |
| Feb 9, 2022 | 18 | MOTION of Appellants Mylan Laboratories Limited and Teva Pharmaceuticals USA, Inc. to extend the time to 04/29/2022 to file brief. Service: 02/09/2022 by email. [830255] [22-1258] [William Burgess] [Entered: 02/09/2022 04:45 PM] (7) |
| Feb 9, 2022 | 17 | Amended Certificate of Interest for Appellant Mylan Laboratories Limited. Service: 02/09/2022 by email. [830250] [22-1258] [Eric Werlinger] [Entered: 02/09/2022 04:36 PM] (4) |
| Feb 9, 2022 | 16 | Amended Certificate of Interest for Appellant Teva Pharmaceuticals USA, Inc.. Service: 02/09/2022 by email. [830044] [22-1258] [William Burgess] [Entered: 02/09/2022 10:53 AM] (2) |
| Jan 11, 2022 | 15 | Docketing Statement for the Appellant Mylan Laboratories Limited. Service: 01/11/2022 by email. [823998] [22-1258] [Deepro Mukerjee] [Entered: 01/11/2022 09:06 PM] (3) |
| Jan 11, 2022 | 14 | Certificate of Interest for Appellant Mylan Laboratories Limited. Service: 01/11/2022 by email. [823997] [22-1258] [Deepro Mukerjee] [Entered: 01/11/2022 09:05 PM] (4) |
| Jan 11, 2022 | 13 | Entry of appearance for Deepro R. Mukerjee; Lance A. Soderstrom; Jitendra Malik; Eric Werlinger; Jillian Schurr as counsel for Appellant Mylan Laboratories Limited. Service: 01/11/2022 by email. [823996] [22-1258] [Deepro Mukerjee] [Entered: 01/11/2022 09:03 PM] (3) |
| Jan 11, 2022 | 12 | Note to File: The following cases are consolidated: 22-1258 Lead with 22-1307 Member Case. The parties must file all documents in the lead appeal only. [823949] [22-1258, 22-1307] [JCW] [Entered: 01/11/2022 04:31 PM] (0) |
| Jan 11, 2022 | 11 | ORDER consolidating appeals (22-1258, 22-1307). Appellants' opening briefs are due no later than February 28, 2022. Service as of this date by the Clerk of Court. [823946] [22-1258, 22-1307] [JCW] [Entered: 01/11/2022 04:30 PM] (2) |
| Dec 29, 2021 | 10 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: re: Doc No. [2], Doc No. [3], Doc No. [4], Doc No. [8], Doc No. [9], ERROR: The documents contain non-compliant signatures. CORRECTION: For future filings, please use an electronic signature consisting of the printed name of the individual preceded by the mark /s/ entered on the signature line. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [821859] [EKD] [Entered: 12/29/2021 04:03 PM] (0) |
| Dec 28, 2021 | 9 | Amended Docketing Statement for the Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. Service: 12/28/2021 by email. [821619] [22-1258] [Barbara Mullin] [Entered: 12/28/2021 05:13 PM] (2) |
| Dec 28, 2021 | 8 | Amended Certificate of Interest for Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. Service: 12/28/2021 by email. [821618] [22-1258] [Barbara Mullin] [Entered: 12/28/2021 05:11 PM] (3) |
| Dec 28, 2021 | 7 | Certificate of Interest for Appellant Teva Pharmaceuticals USA, Inc.. Service: 12/28/2021 by email. [821617] [22-1258] [John O'Quinn] [Entered: 12/28/2021 05:04 PM] (4) |
| Dec 28, 2021 | 6 | Docketing Statement for the Appellant Teva Pharmaceuticals USA, Inc.. Service: 12/28/2021 by email. [821615] [22-1258] [John O'Quinn] [Entered: 12/28/2021 04:58 PM] (2) |
| Dec 28, 2021 | 5 | Entry of appearance for John C. O'Quinn; William H. Burgess; Jeanna Wacker; Christopher Jagoe; Mira Mulvaney as counsel for Appellant Teva Pharmaceuticals USA, Inc.. Service: 12/28/2021 by email. [821610] [22-1258] [John O'Quinn] [Entered: 12/28/2021 04:50 PM] (2) |
| Dec 23, 2021 | 4 | Certificate of Interest for Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. Service: 12/23/2021 by email. [821151] [22-1258] [Barbara Mullin] [Entered: 12/23/2021 07:37 PM] (3) |
| Dec 23, 2021 | 3 | Docketing Statement for the Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. Service: 12/23/2021 by email. [821150] [22-1258] [Barbara Mullin] [Entered: 12/23/2021 07:36 PM] (2) |
| Dec 23, 2021 | 2 | Entry of appearance for Barbara L. Mullin; Andrew D. Cohen; and Aron Russell Fischer as counsel for Appellees Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc.. Service: 12/23/2021 by email. [821149] [22-1258]--[Edited 12/29/2021 by EKD to correct docket text] [Barbara Mullin] [Entered: 12/23/2021 07:34 PM] (2) |
| Dec 14, 2021 | 1 | Appeal docketed. Received: 12/13/2021. [818585]Entry of Appearance is due on 12/28/2021. Certificate of Interest is due on 12/28/2021. Docketing Statement is due on 12/28/2021. Appellant's brief is due on 02/14/2022. [JCW] [Entered: 12/14/2021 03:10 PM] (39) |
